Skip to main content

Liver Metastases clinical trials at UC Cancer

1 research study open to eligible people

Showing trials for
  • Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

    open to eligible people ages 18 years and up

    The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

    at UCSF

Last updated: